Browse our anti-Indoleamine 2,3-Dioxygenase 1 (IDO1) Antibodies

Cow (Bovine) Indoleamine 2,3-Dioxygenase 1 (IDO1) interaction partners

1. Differential expression of CD25 (show IL2RA Antibodies) and IDO mRNA with high and low virulence bovine viral diarrhea virus might reflect temporal differences in transcription during the immune response elicited by these viral strains.

2. IDO may be involved in downregulating immune responses to M. avium subsp. paratuberculosis and other virulent mycobacteria, which may be an example of the pathogen harnessing host immunoregulatory pathways to aid survival.

3. INDO participates in IFN-gama-induced death of bovine luteal cells, through a mechanism that involves degradation of tryptophan, thereby reducing tryptophan concentrations to a point insufficient to meet luteal cells needs

Rhesus Monkey Indoleamine 2,3-Dioxygenase 1 (IDO1) interaction partners

1. SIV-infected macaques exhibiting progression to AIDS displayed greater expression of TGF-beta (show TGFB1 Antibodies) and indoleamine 2,3 dioxygenase in CD8 (show CD8A Antibodies)+ T cells from mesentric lymph nodes.

Human Indoleamine 2,3-Dioxygenase 1 (IDO1) interaction partners

1. In non-ST segment elevation myocardial infarction, the tolerogenic mechanism of the immune response related to IDO production by activated monocytes derived dendritic cells is altered, supporting their role in T-cell dysregulation.

2. These data suggest that the expression of immunosuppressive molecules, including PD-1 (show PDCD1 Antibodies) ligands and IDO1, by macrophage/microglia may be involved in immune evasion of lymphoma cells.

3. Our data demonstrate that high intratumoral IDO1 mRNA levels correlate with a poor glioblastoma (GBM) patient prognosis. It also confirms the positive correlation between increased GBM IDO1 levels and human-infiltrating T cells

4. Among the 89 patients, CD274 (show CD274 Antibodies), LAG3 (show LAG3 Antibodies), and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274 (show CD274 Antibodies), CTLA4 (show CTLA4 Antibodies), and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively.

5. Multivariate analysis indicated indoleamine 2,3-dioxygenase (IDO) expression as independent prognostic factors in overall survival (OS).

6. these findings suggest that IDO1 promoter methylation regulates anti-immune responses in breast cancer subtypes and could be used as a predictive biomarker for IDO1 inhibitor-based immunotherapy.

7. main biological and actionable difference between OSCC from NSND and SD lies in the immune microenvironment, suggesting a higher clinical benefit of PD-L1 (show CD274 Antibodies) and IDO1 inhibition in OSCC from NSND

8. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 (show PDCD1 Antibodies) checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma (show MOK Antibodies), and non-small cell lung cancer

9. This first-in-human phase I study investigated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1

10. Fumaric acid esters inhibit both IDO expression and enzymatic activity leading to a modulation of tryptophan degradation.

Mouse (Murine) Indoleamine 2,3-Dioxygenase 1 (IDO1) interaction partners

1. The treatment of Salmonella enterica serovar choleraesuis or resveratrol in murine melanoma cells demonstrated the ability of reducing IDO1 production through upregulating Cx43 (show GJA1 Antibodies).

2. Study showed that the knockout of IDO prevented vascular smooth muscle cells apoptosis in AngII -treated Ldlr (show LDLR Antibodies)-/- mice fed with HFD, suggesting a detrimental role of IDO in abdominal aortic aneurysm formation.

3. The KYNurenine pathway of IDO1-mediated Tryptophan metabolism plays a critical role in depressive symptoms associated with IFN-alpha (show IFNA Antibodies) therapy.

4. IDO is a critical regulator of acute pulmonary inflammation .

5. Data suggest that Indoleamine 2,3-dioxygenase 1 (IDO1) appears to be a potential hallmark of liver lesions, and its deficiency protects mice from CCl4 (show CCL4 Antibodies)-induced fibrosis mediated by Th17 cells down-regulation and tryptophan 2,3-dioxygenase (TDO (show TDO2 Antibodies)) compensatory increase.

6. Findings suggest non-redundant neurophysiological roles for indoleamine 2,3-dioxygenase 1, indoleamine 2,3-dioxygenase 2 (show IDO2 Antibodies) and tryptophan 2,3-dioxygenase (show TDO2 Antibodies) in modulating brain activities and metabolism.

7. These results show IDO is upregulated with RSV infection and this upregulation likely participates with IFN-gamma (show IFNG Antibodies) in inhibition of virus replication and suppression of some host cell responses to infection.

8. Lipopolysaccharide (LPS (show TLR4 Antibodies)) stimulation increased the expression and activity of the immunoregulatory enzyme IDO1 in hepatic stellate cells (HSCs), and LPS (show TLR4 Antibodies)/HSCs stimulated aryl hydrocarbon receptor (AhR (show AHR Antibodies)) signaling in cocultured regulatory T cells.

9. this study shows that the presence of IFN-alpha (show IFNA Antibodies) at antigen sensitization activates an IDO1/TGF-beta (show TGFB1 Antibodies)-dependent anti-inflammatory program that upon antigenic rechallenge prevents inflammation via plasmacytoid dendritic cells

10. Across strains, networks depicted a predominance of genes under-expressed in microglia relative to macrophages that may be a precursor for the different response of both cell types to challenges. The detected transcriptome differences enhance the understanding of the role of IDO1 in the microglia transcriptome under unchallenged conditions.

Pig (Porcine) Indoleamine 2,3-Dioxygenase 1 (IDO1) interaction partners